Clinical trial · Interventional
Adding L-Carnitine to Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome
NCT03630341CI-TRIAL-00034344completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Polycystic ovary syndrome is one of the most common endocrine disorders, affecting about 6-10% of women in their reproductive age. Anovulation and hyperandrogenism are often present together with hyperinsulinaemia and insulin resistance
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Clomiphene Citrate 50mg | Drug | — | UNRESOLVED |
| L-carnitine | Drug | — | UNRESOLVED |
| Placebo Oral Tablet | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- study group
- description
- This group will receive oral clomiphene citrate 50 mg tablet, two times per day from the third day of the cycle until the seventh day of the cycle plus oral carnitine 1g tablet, three times per day from the third day until the day of the pregnancy test.
- interventionNames
- Drug: Clomiphene Citrate 50mg
- Drug: L-carnitine
- type
- ACTIVE_COMPARATOR
- label
- control group
- description
- This group will receive oral clomiphene citrate 50 mg tablet, two times per day from the third day of the cycle until the seventh day of the cycle plus oral placebo tablet, three times per day from the third day until the day of the pregnancy test.
- interventionNames
- Drug: Clomiphene Citrate 50mg
- Drug: Placebo Oral Tablet
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: * Primary or secondary infertility. * Normal Hysterosalpingo-graphy * Normal Semen analysis of the husband. Exclusion Criteria: * Patient's refusal. * Male factors of infertility and/or abnormal Hysterosalpingo-graphy * Hyperprolactinemia (prolactin ≥ 22 ng/dl). * FSH on day 3 \> 15 mIU/mL. * Gross ovarian pathology diagnosed by ultrasound.
References
Publications (0)
Data not yet available
No reference posted for this study.